Sharp decline in hydroxychloroquine dosing—analysis of 17,797 initiators from 2007 to 2016

Clinical Rheumatology

Volumn 37, Issue 7, 2018, Pages 1853-1859

  Melles, Ronald B ^a   Jorge, April M ^b   Marmor, Michael F ^c   Zhang, Yuqing ^b   Choi, Hyon K ^b  

^a KAISER PERMANENTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Preventative medicine; Rheumatic diseases; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

HYDROXYCHLOROQUINE; ANTIRHEUMATIC AGENT;

ADULT; ALOPECIA; ARTICLE; BODY MASS; BODY WEIGHT; DERMATITIS; DERMATOLOGY; DRUG DOSE; DRUG INDICATION; FEMALE; GRANULOMA ANNULARE; HUMAN; LICHEN PLANUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNDERWEIGHT; URTICARIA; CHEMICALLY INDUCED; DOSE CALCULATION; PROTOCOL COMPLIANCE; RETINA DISEASE; STATISTICAL MODEL;

ANTIRHEUMATIC AGENTS; DRUG DOSAGE CALCULATIONS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYCHLOROQUINE; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RETINAL DISEASES;

EID: 85046022298     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-018-4116-0     Document Type: Article

References (26)

1. Ruiz-Irastorza G, Khamashta M (2008) Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 17:271–273
2. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, Isenberg D, Kallenberg CG, Khamashta M, Piette JC, Schneider M, Smolen J, Sturfelt G, Tincani A, van Vollenhoven R, Gordon C, Boumpas DT (2008) Task force of the ESCfICSITEULAR recommendations for the management of systemic lupus erythematosus Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67(2):195–205. 10.1136/ard.2007.070367
3. Petri M (2011) Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 13:77–80
4. Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, Vila LM, Reveille JD, Group LS (2007) Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66(9):1168–1172. 10.1136/ard.2006.068676
5. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54(8):2550–2557. 10.1002/art.21955
6. Clowse ME, Magder L, Witter F, Petri M (2006) Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 54(11):3640–3647. 10.1002/art.22159
7. Cairoli E, Rebella M, Danese N, Garra V, Borba EF (2012) Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 21:1178–1182
8. O’Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S, Keystone E (2013) Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369(4):307–318. 10.1056/NEJMoa1303006
9. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69(1):20–28. 10.1136/ard.2008.101766
10. Costedoat-Chalumeau N, Dunogue B, Leroux G, Morel N, Jallouli M, Le Guern V, Piette JC, Brezin AP, Melles RB, Marmor MF (2015) A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol 49(3):317–326. 10.1007/s12016-015-8469-8
11. LG D, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T (1997) Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 40(8):1482–1486
12. Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M (2003) The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine. Ophthalmology 110(7):1321–1326. 10.1016/s0161-6420(03)00409-3
13. Wolfe F, Marmor MF (2010) Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62(6):775–784. 10.1002/acr.20133
14. Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132(12):1453–1460. 10.1001/jamaophthalmol.2014.3459
15. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF (2011) Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118(2):415–422. 10.1016/j.ophtha.2010.11.017
16. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of O (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123(6):1386–1394. 10.1016/j.ophtha.2016.01.058
17. Devine B (1974) Case number 25: gentamicin therapy. Drug Intelligence and Clin Pharm 8:650–655
18. Gianfrancesco MA, Schmajuk G, Haserodt S, Trupin L, Izadi Z, Jafri K, Shiboski S, Sirota M, Adams Dudley R, Yazdany J (2017) Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety. Rheumatol Int 37:1611–1618. 10.1007/s00296-017-3782-6
19. Braslow RA, Shiloach M, Macsai MS (2017) Adherence to hydroxychloroquine dosing guidelines by rheumatologists: an electronic medical record-based study in an integrated health care system. Ophthalmology 124:604–608. 10.1016/j.ophtha.2016.12.021
20. Feldman CH, Collins J, Zhang Z, Subramanian SV, Solomon DH, Kawachi I, Costenbader KH (2018) Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. Semin Arthritis Rheum. 10.1016/j.semarthrit.2018.01.002
21. Anthropometric Reference Data for Children and Adults: United States, 2007–2010 (2012 Oct). US Department of Health and Human Services, CDC 11 (252)
22. Chasset F, Arnaud L, Costedoat-Chalumeau N, Zahr N, Bessis D, Frances C (2016) The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): an open-label prospective pilot study. J Am Acad Dermatol 74(4):693–699.e693. 10.1016/j.jaad.2015.09.064
23. Frances C, Cosnes A, Duhaut P, Zahr N, Soutou B, Ingen-Housz-Oro S, Bessis D, Chevrant-Breton J, Cordel N, Lipsker D, Costedoat-Chalumeau N (2012) Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 148(4):479–484. 10.1001/archdermatol.2011.2558
24. Durcan L, Clarke WA, Magder LS, Petri M (2015) Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol 42(11):2092–2097. 10.3899/jrheum.150379
25. Browning DJ, Lee C, Rotberg D (2014) The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women.Clin Ophthalmol(Auckland, NZ) 8:1401–1407. doi:10.2147/opth.s66531
26. Krieger N (1992) Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 82(5):703–710